NCT03019640
- Conditions
- Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +17 more
- Locations
-
- M D Anderson Cancer Center Houston, Texas, United States
Clinical trial condition
Refractory Diffuse Large B-Cell Lymphoma
Explore clinical trials studying Refractory Diffuse Large B-Cell Lymphoma. Study availability and eligibility vary by location and protocol.
66 public trials
20 recruiting studies
Refractory Diffuse Large B-Cell Lymphoma trial results
NCT03305445
- Conditions
- Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +10 more
- Locations
-
- Icahn School of Medicine at Mount Sinai New York, United States
NCT02405078
- Conditions
- Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +10 more
- Locations
-
- M D Anderson Cancer Center Houston, Texas, United States
NCT01865617
- Conditions
- CD19-Positive Neoplastic Cells Present, Chronic Disease, Disease Attributes, +32 more
- Locations
-
- Fred Hutch/University of Washington Cancer Consortium Seattle, Washington, United States
NCT02077166
- Conditions
- Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +10 more
- Locations
-
- University of Alabama Birmingham, Alabama, United States
- Banner MD Anderson Cancer Center Gilbert, Arizona, United States
- Cedar Sinai Medical Center Los Angeles, California, United States
- UCLA Medical Center Los Angeles, California, United States
NCT03688152
- Conditions
- Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +10 more
- Locations
-
- University of Arizona Cancer Center Tucson, Arizona, United States
- UCLA Healthcare Hematology-Oncology Santa Monica, California, United States
- Clinical Research Alliance Lake Success, New York, United States
Completed
Pembrolizumab and Ibrutinib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
NCT02950220
- Conditions
- B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classical Hodgkin Lymphoma, Blood Protein Disorders, Burkitt Lymphoma, +46 more
- Locations
-
- Ohio State University Comprehensive Cancer Center Columbus, Ohio, United States
Completed
Alisertib and Romidepsin in Treating Patients With Relapsed or Refractory B-Cell or T-Cell Lymphomas
NCT01897012
- Conditions
- Burkitt Lymphoma, DNA Virus Infections, Epstein-Barr Virus Infections, +36 more
- Locations
-
- M D Anderson Cancer Center Houston, Texas, United States
NCT02976857
- Conditions
- Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +9 more
- Locations
-
- Hematological Department, People's Hospital of Jiangsu Province Nanjing, Jiangsu, China
NCT02219737
- Conditions
- CD20 Positive, Hemic and Lymphatic Diseases, Immune System Diseases, +11 more
- Locations
-
- Memorial Sloan-Kettering Cancer Center New York, United States